journal
MENU ▼
Read by QxMD icon Read
search

Translational Lung Cancer Research

journal
https://read.qxmd.com/read/30788240/combining-stereotactic-body-radiation-therapy-with-immunotherapy-current-data-and-future-directions
#1
REVIEW
Alexander J Lin, Michael Roach, Jeffrey Bradley, Clifford Robinson
Stereotactic body radiation therapy (SBRT) offers excellent local control of early-stage non-small cell lung cancer (NSCLC), but there currently is a need for tolerable systemic therapy to address regional and distant disease progression. One potential option is immunotherapy, which in metastatic NSCLC has shown promise for sustained disease control in a subset of patients. There is also growing evidence for a clinical synergy between radiation and immunotherapy, with several ongoing trials studying the abscopal effect...
February 2019: Translational Lung Cancer Research
https://read.qxmd.com/read/30788239/stereotactic-ablative-body-radiation-for-oligometastatic-and-oligoprogressive-disease
#2
REVIEW
Matthew S Ning, Daniel R Gomez, John V Heymach, Stephen G Swisher
Stage IV non-small cell lung cancer (NSCLC) exists on a spectrum, with a subset of patients presenting with oligometastatic disease involving only a limited number of distant sites. For these patients, local consolidative therapy (LCT) has been demonstrated to improve outcomes through ablation or cytoreduction of metastatic disease, as shown in an increasing number of randomized controlled trials. In particular, stereotactic ablative body radiation (SABR) has emerged as a feasible treatment modality for elimination of oligometastatic sites...
February 2019: Translational Lung Cancer Research
https://read.qxmd.com/read/30788238/the-optimal-treatment-approaches-for-stage-i-small-cell-lung-cancer
#3
REVIEW
Amy C Moreno, Steven H Lin
Although small cell lung cancer (SCLC) represents less than one-sixth of all lung cancer cases, it is an aggressive disease with a high metastatic potential to various sites including the brain. Most landmark trials assessing individual therapy benefits for SCLC dichotomized patients as having either limited or extensive disease. Over the last decade, however, there has been a clear shift towards categorizing and analyzing survival patterns using a more thorough staging system that accounts for tumor size and the degree of nodal or metastatic disease burden...
February 2019: Translational Lung Cancer Research
https://read.qxmd.com/read/30788237/stereotactic-body-radiotherapy-as-salvage-treatment-for-recurrence-of-non-small-cell-lung-cancer-after-prior-surgery-or-radiotherapy
#4
REVIEW
Michael T Milano, Feng-Ming Spring Kong, Benjamin Movsas
Treatment options for thoracic recurrences of non-small cell lung cancer (NSCLC) are limited. Stereotactic body radiation therapy (SBRT) is an emerging, potentially effective technology to manage recurrent NSCLC, although with limited prospective studies. This work reviews the outcomes of patients undergoing salvage SBRT for pulmonary recurrences after prior resection or prior radiotherapy for NSCLC. Following salvage SBRT, after prior external beam radiation (SBRT or conventionally fractionated), the 2-year overall survival (OS) ranged from 37% to 79% in 11 of the studies (397 patients) reviewed here, while the 2-year local control (LC) ranged from 37% to 90% in 6 studies that reported that outcome...
February 2019: Translational Lung Cancer Research
https://read.qxmd.com/read/30788236/approaches-to-stereotactic-body-radiation-therapy-for-large-%C3%A2-5-centimeter-non-small-cell-lung-cancer
#5
REVIEW
Vivek Verma, Charles B Simone
Although larger (≥5 cm) node-negative non-small cell lung cancer (NSCLC) lesions are altogether uncommon, their incidence may increase following the implementation of lung cancer screening. A rigorous assessment of stereotactic body radiation therapy (SBRT) for these challenging cases is imperative not only owing to concerns of increased risks when delivering ablative doses to large volumes, but also due to lack of prospective data, as these patients were excluded from seminal phase II SBRT trials. In addition to appraising the available institutional or multi-institutional experiences, multiple strategies to reduce toxicities are discussed...
February 2019: Translational Lung Cancer Research
https://read.qxmd.com/read/30788235/stereotactic-body-radiotherapy-for-centrally-located-stage-i-non-small-cell-lung-cancer
#6
REVIEW
Andrew Bang, Andrea Bezjak
Stereotactic body radiotherapy (SBRT) has become the standard of care for the treatment of early stage non-small cell lung cancer in high risk or medically inoperable patients. It is very well tolerated when given to peripherally located tumors and is associated with high rates of local control. Centrally located tumors represent a bigger challenge as they are closer to a number of critical structures, namely the major bronchi, esophagus, large vessels and brachial plexus, that can be damaged by the high ablative doses of SBRT needed for optimal tumor control...
February 2019: Translational Lung Cancer Research
https://read.qxmd.com/read/30788234/the-evolving-toxicity-profile-of-sbrt-for-lung-cancer
#7
REVIEW
Marcher Thompson, Kenneth E Rosenzweig
Stereotactic body radiation therapy (SBRT) is an effective and well tolerated treatment for early stage non-small cell lung cancer (NSCLC). The high doses used in thoracic SBRT can sometimes cause adverse effects ranging from mild fatigue and transient esophagitis to fatal events such as pneumonitis or hemorrhage. Efforts continue to expand in both the utility of this technique as well as our understanding of the mechanisms of the adverse effects it can cause. In this review, we discuss the current literature regarding the potential mechanisms, dosimetric constraints and toxicities associated with SBRT alone and in conjunction with definitive chemoradiotherapy and immunotherapy...
February 2019: Translational Lung Cancer Research
https://read.qxmd.com/read/30788233/medically-inoperable-stage-i-non-small-cell-lung-cancer-best-practices-and-long-term-outcomes
#8
REVIEW
J Isabelle Choi
Early-stage non-small cell lung cancer (ES-NSCLC) currently represents a minority of all NSCLC diagnoses but, with ongoing refinement and improvement of treatment approaches, is a group with increasing likelihood of long-term disease control and survival. A significant proportion of this population will not be optimal candidates for definitive surgical resection due to tumor characteristics, patient frailty, or comorbid status. The clinical evidence to support the use of stereotactic body radiation therapy (SBRT) in patients with medically inoperable stage I NSCLC is growing as long-term data are obtained...
February 2019: Translational Lung Cancer Research
https://read.qxmd.com/read/30788232/optimizing-immobilization-margins-and-imaging-for-lung-stereotactic-body-radiation-therapy
#9
REVIEW
Jason K Molitoris, Tejan Diwanji, James W Snider, Sina Mossahebi, Santanu Samanta, Nasarachi Onyeuku, Pranshu Mohindra, J Isabelle Choi, Charles B Simone
The simultaneous advancement of technologies for the delivery of precisely targeted radiation therapy and the paradigm shift to substantial hypofractionation have led to significant improvements in the treatment of early stage non-small cell lung cancer (ES-NSCLC). Stereotactic body radiation therapy (SBRT) has become a well-established option for the treatment of ES-NSCLC and is now becoming widely available within the radiation oncology community. Implementation of this technique, however, requires highly accurate target delineation, thorough evaluation of tumor motion, and improved on-board imaging at the time of treatment for patient alignment, each of which is critical for successful tumor control and mitigation of risks to normal tissues...
February 2019: Translational Lung Cancer Research
https://read.qxmd.com/read/30788231/predictors-of-pneumonitis-free-survival-following-lung-stereotactic-body-radiation-therapy
#10
Sibo Tian, Jeffrey M Switchenko, Richard J Cassidy, Chase E Escott, Richard Castillo, Pretesh R Patel, Walter J Curran, Kristin A Higgins
Background: Radiation pneumonitis is a common toxicity following lung stereotactic body radiation therapy (SBRT). We explored whether motion management technique, in conjunction with patient and treatment characteristics, is a predictor of radiation pneumonitis-free survival (PNFS). Methods: A single institution multi-center lung SBRT database was retrospectively reviewed. PNFS was defined as time to earliest onset of radiation pneumonitis or last clinical follow-up...
February 2019: Translational Lung Cancer Research
https://read.qxmd.com/read/30788230/empiric-radiotherapy-for-lung-cancer-collaborative-group-multi-institutional-evidence-based-guidelines-for-the-use-of-empiric-stereotactic-body-radiation-therapy-for-non-small-cell-lung-cancer-without-pathologic-confirmation
#11
REVIEW
Abigail T Berman, Salma K Jabbour, Anil Vachani, Cliff Robinson, J Isabelle Choi, Pranshu Mohindra, Ramesh Rengan, Jeffrey Bradley, Charles B Simone
The standard of care for managing early stage non-small cell lung cancer (NSCLC) is definitive surgical resection. Stereotactic body radiation therapy (SBRT) has become the standard treatment for patient who are medically inoperable, and it is increasingly being considered as an option in operable patients. With the growing use of screening thoracic CT scans for patients with a history of heavy smoking, as well as improved imaging capabilities, the discovery of small lung nodes has become a common dilemma. As a result, clinicians are increasingly faced with managing lung nodules in patients in whom diagnostic biopsy is not safe or feasible...
February 2019: Translational Lung Cancer Research
https://read.qxmd.com/read/30788229/the-current-and-future-faces-of-stereotactic-body-radiation-therapy-for-thoracic-malignancies
#12
J Isabelle Choi, Charles B Simone
No abstract text is available yet for this article.
February 2019: Translational Lung Cancer Research
https://read.qxmd.com/read/30705865/raymond-u-osarogiagbon-lung-cancer-is-a-global-challenge-that-needs-our-close-cooperation
#13
Brad Li
No abstract text is available yet for this article.
December 2018: Translational Lung Cancer Research
https://read.qxmd.com/read/30705864/elderly-patients-with-stage-iii-nsclc-survive-longer-when-chemotherapy-is-added-to-radiotherapy-fortune-favours-the-bold
#14
EDITORIAL
Surein Arulananda, Paul Mitchell
No abstract text is available yet for this article.
December 2018: Translational Lung Cancer Research
https://read.qxmd.com/read/30705863/role-of-immune-checkpoint-blockers-in-patients-with-egfr-mutation
#15
EDITORIAL
Jeffrey Ward, Daniel Morgensztern
No abstract text is available yet for this article.
December 2018: Translational Lung Cancer Research
https://read.qxmd.com/read/30705862/stat3-cyclic-oligonucleotide-decoy-a-new-therapeutic-avenue-for-nsclc
#16
EDITORIAL
Lennard Y W Lee, Summaya Mohammad, Thomas Starkey, Siow-Ming Lee
No abstract text is available yet for this article.
December 2018: Translational Lung Cancer Research
https://read.qxmd.com/read/30705861/immunotherapy-in-tyrosine-kinase-inhibitor-na%C3%A3-ve-advanced-epidermal-growth-factor-receptor-mutant-non-small-cell-lung-cancer-driving-down-a-precarious-road-in-driver-mutated-lung-cancer
#17
EDITORIAL
Rebecca Yin Tay, Christoph Jakob Ackermann, Raffaele Califano
No abstract text is available yet for this article.
December 2018: Translational Lung Cancer Research
https://read.qxmd.com/read/30705860/aromatase-inhibitors-combined-with-aspirin-to-prevent-lung-cancer-in-preclinical-models
#18
EDITORIAL
Patricia A Young, Richard J Pietras
No abstract text is available yet for this article.
December 2018: Translational Lung Cancer Research
https://read.qxmd.com/read/30705859/immunotherapies-in-the-management-of-epidermal-growth-factor-receptor-mutated-non-small-cell-lung-cancer-a-role-will-be-found
#19
EDITORIAL
Francesca Casaluce, Cesare Gridelli
No abstract text is available yet for this article.
December 2018: Translational Lung Cancer Research
https://read.qxmd.com/read/30705858/editorial-for-longitudinal-cell-free-dna-analysis-in-patients-with-small-cell-lung-cancer-reveals-dynamic-insights-into-treatment-efficacy-and-disease-relapse
#20
EDITORIAL
Michael Fleischhacker, Bernd Schmidt
No abstract text is available yet for this article.
December 2018: Translational Lung Cancer Research
journal
journal
49936
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"